Pharmacokinetics and Safety of 3 Months of Weekly Rifapentine and Isoniazid for Tuberculosis Prevention in Pregnant Women.

Journal:

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Volume: 74, Issue: 9

Published:

May 3, 2022

PMID:

34323955

Authors:

Jyoti S Mathad JS, Rada Savic R, Paula Britto P, Priya Jayachandran P, Lubbe Wiesner L, Grace Montepiedra G, Jennifer Norman J, Nan Zhang N, Ellen Townley E, Nahida Chakhtoura N, Sarah Bradford S, Sandesh Patil S, Stephanie Popson S, Tsungai Chipato T, Vanessa Rouzier V, Deborah Langat D, Amphan Chalermchockcharoentkit A, Portia Kamthunzi P, Amita Gupta A, Kelly E Dooley KE

Access Paper

DOI: 10.1093/cid/ciab665

PMID: 34323955

Abstract:

Pregnancy increases the risk of tuberculosis and its complications. A 3-month regimen of weekly isoniazid and rifapentine (3HP) is safe and effective for tuberculosis prevention in adults and children, including those with HIV, but 3HP has not been evaluated in pregnancy.

Courtesy of the U.S. National Library of Medicine